File(s) not publicly available
Plasma IP-10 could identify early lung disease in severe COVID-19 patients
journal contributionposted on 14.12.2021, 09:07 authored by Hwee Siew Howe, Li Min Ling, Elampirai Elangovan, Shawn Vasoo, Mohammad Yazid Abdad, Bernard Yu Hor Thong, Kok Ooi Kong, Pui Lam Bernard LeungPui Lam Bernard Leung
The first case of infection with the novel SARS-Coronavirus-2 (SARS-CoV-2) was reported in Singapore in January 2020. Older age, obesity, comorbidities and male sex are risk factors for more severe disease. However the immune interactions between SARS-CoV-2 and the host in local multi-ethnic Asian patients remains unclear. Our objective was to investigate plasma levels of interferon gamma inducible protein-10 (IP-10) in patients with Coronavirus-2019 disease (COVID-19) and their correlation with disease manifestations. Elevated plasma IP-10 levels were observed in 72 hospitalised COVID-19 patients with symptomatic disease at the National Centre of Infectious Disease (NCID, Singapore), and were significantly correlated with increased levels of C-reactive protein (CRP), lactate dehydrogenase (LDH), and changes in neutrophil and lymphocyte count. In addition, COVID-19 patients with early chest X-ray changes exhibited higher plasma of IP-10 than those without. Logistic regression incorporating laboratory variables including elevated CRP, thrombocytosis and high IP-10 levels exceeding 200 pg/ml demonstrated significant univariate association with severe COVID-19 disease and requirement for intensive care monitoring.